NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers Health, Inc. investors who were adversely affected by alleged securities fraud between April 29, 2025 and June 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.co ...

NEW YORK, July 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers Health, Inc. investors who were adversely affected by alleged securities fraud between April 29, 2025 and June 23, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslr ...

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=156058&from=3 CLASS PERIOD: A ...

SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company’s executives. Sookdeo v. Hims & Hers Health, Inc., et al., No. 3:25-cv-05315 (N.D. Cal.) and Yaghsizian v. Hims & Hers Health, Inc. et al., No. 3:25-cv-05321 (N.D. Cal.). Together, the cases seek to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025. The ...

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers Health, Inc. investors who were adversely affected by alleged securities fraud between April 29, 2025 and June 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.co ...

NEW YORK, July 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=155418&from=4CLASS PERIOD: April 29, ...

Core Viewpoint - Edelson Lechtzin LLP is investigating securities fraud claims against Hims & Hers Health, Inc. related to its partnership with Novo Nordisk, which may have misled investors regarding the nature of the collaboration and its implications for the company's stock value [1][4]. Company Overview - Hims & Hers Health, Inc. is a telehealth and online pharmacy company that provides prescription and over-the-counter medications, mental health services, and personal care products through a direct-to-consumer platform in the U.S. and the U.K. [3]. Securities Fraud Claims - The complaint alleges that Hims & Hers made materially false and misleading statements and failed to disclose critical facts about its partnership with Novo Nordisk during the class period from April 29, 2025, to June 23, 2025 [4]. - Specifically, Hims & Hers allegedly engaged in deceptive promotion and sale of Novo Nordisk's Wegovy® weight loss drug, creating a substantial risk of termination of the partnership [4]. Partnership Details - On April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk, which included the immediate sale of a bundled offering of Wegovy® on its platform [5]. - However, on June 23, 2025, Novo Nordisk terminated the partnership, citing Hims & Hers' failure to comply with legal standards regarding the sale of compounded drugs and deceptive marketing practices that jeopardized patient safety [5]. Stock Impact - Following the termination announcement by Novo Nordisk, Hims & Hers' stock price dropped by $22.24 per share, representing a decline of 34.63%, closing at $41.98 per share on June 23, 2025 [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of securities law violations related to misleading statements and the promotion of unsafe products [3][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Hims between April 29, 2025, and June 22, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Hims, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [3][7]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which jeopardized patient safety and misled investors about the company's operations and prospects [5]. Group 2: Partnership Termination and Stock Impact - Novo Nordisk announced the termination of its partnership with Hims on June 23, 2025, citing Hims' failure to comply with legal standards and the promotion of unsafe compounded drugs [6]. - Following the announcement, Hims' stock price dropped by $22.24, or 34.6%, closing at $41.98 per share, resulting in significant losses for investors [6]. Group 3: Call for Information - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Hims' conduct [8].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements and the promotion of illegitimate products [1][2][3] Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk A/S on April 29, 2025, to sell a bundled offering of Wegovy® [2] Allegations and Impact - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2][3] - Following Novo Nordisk's announcement on June 23, 2025, to terminate its partnership with Hims & Hers due to these deceptive practices, Hims & Hers' stock price dropped by over 34% [3] Legal Process - Investors who purchased Hims & Hers securities during the specified class period can seek to be appointed as lead plaintiff in the class action lawsuit [4] - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [4] Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [5]

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between April 29, 2025, and June 23, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which jeopardized patient safety [2]. - It is alleged that this situation posed a significant risk of termination of the Company's collaboration with Novo Nordisk [2]. - The defendants' positive statements regarding the Company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].